Review
Immunology and immunotherapy of human malignant melanoma
- PMID: 2937585
Item in Clipboard
Review
Immunology and immunotherapy of human malignant melanoma
Dermatol Clin.
1985 Apr.
Abstract
One theoretically attractive approach to the treatment of melanoma, which has captivated the imagination of physicians since the turn of the century, is to harness the unique and powerful recognition properties of the immune system to identify and destroy melanoma cells selectively wherever they may be. This review summarizes the complex role of the immune system in tumor growth, some of the immunotherapeutic approaches developed to treat human melanoma, and progress in the development of melanoma tumor antigen vaccines.
Similar articles
-
Immunotherapy of malignant melanoma.Dermatol Clin. 1991 Oct;9(4):669-82. Dermatol Clin. 1991. PMID: 1718648 Review.
-
Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.Semin Cancer Biol. 2003 Dec;13(6):449-59. doi: 10.1016/j.semcancer.2003.09.009. Semin Cancer Biol. 2003. PMID: 15001164 Review.
-
[Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].Dermatol Monatsschr. 1987;173(8):441-5. Dermatol Monatsschr. 1987. PMID: 3311840 German. No abstract available.
-
Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.Clin Cancer Res. 1995 Jul;1(7):705-13. Clin Cancer Res. 1995. PMID: 9816036
-
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4. J Immunother Emphasis Tumor Immunol. 1996. PMID: 8859727
Cited by
-
Tumor vaccines.Cancer Metastasis Rev. 1990 Jul;9(1):81-91. doi: 10.1007/BF00047590. Cancer Metastasis Rev. 1990. PMID: 2208570 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical